Analysts Set Oculis Holding AG (NASDAQ:OCS) Price Target at $43.86

Oculis Holding AG (NASDAQ:OCS) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $43.8571.

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Oculis in a research report on Friday, December 19th. They set an “overweight” rating and a $38.00 price objective on the stock. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright boosted their price objective on Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Needham & Company LLC upped their target price on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of OCS. China Universal Asset Management Co. Ltd. boosted its holdings in Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC bought a new stake in shares of Oculis in the 4th quarter worth approximately $80,000. Millennium Management LLC bought a new stake in shares of Oculis in the fourth quarter valued at $312,000. Bosun Asset Management LLC purchased a new stake in Oculis during the second quarter valued at about $378,000. Finally, Marshall Wace LLP purchased a new stake in shares of Oculis during the 2nd quarter valued at approximately $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Price Performance

Oculis stock opened at $26.63 on Friday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -11.73 and a beta of 0.48. Oculis has a 52-week low of $14.00 and a 52-week high of $30.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96. The stock’s 50 day moving average price is $27.45 and its two-hundred day moving average price is $22.72.

Oculis (NASDAQ:OCS) last released its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. On average, equities analysts predict that Oculis will post -2.09 earnings per share for the current year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.